Totožnost Předsedajícího byla notáři prokázána. -------------------------------------------------------------------------- 4. Kateřinou Hájkovou, LL.M., datum narození 03.06.1982, adresa místa pobytu Křižíkova 220/91, Karlín, 186 00 Praha 8, advokáta, evidenční číslo ČAK 13682, spolupracujícího s PRK Partners s.r.o., advokátní kancelář, IČO 266 92 392, se sídlem Jáchymova 26/2, Staré Město, 110 00 Praha 1, na základě plných moci, které jsou přílohami číslo 3 a číslo 4 tohoto notářského zápisu, mající 980 hlasů, ---------------------------------------------------- - prohlášením Předsedajícího dle článku II., že valná hromada je způsobilá přijímat Rozhodnutí. Petr Elšík, -3-, notář v Litoměřicích ---------------------------------------------------------------- .

December 1, 2023 December 1, 2023 Rose, Vice President, Marketing and Communications, Avient Corporation, +1 440-930-3162, kyle.rose@avient.com

MEVOPUR Colors for Ophthalmic Closures Application Bulletin_CN8.18-1 * 可根据要求提供FDA/EU合规信息 应用公告 用于眼科药物容器盖的 着色剂MEVOPUR™ 用于眼部（眼科）用药物容器盖的MEVOPUR标 准母粒系列产品符合美国眼科学会（AAO）的颜 色标准。 法规支持 经过预测试的原材料： - ISO 10993-1 - USP 第、章（VI类） - USP （指南），6.2.3 可萃取元素； USP - ICHQ3D/USP 2 可萃取金属 - 欧洲药典 3.1 聚烯烃（如适用） FDA发布的注册药品管理档案（III类）和/或医 疗器械管理档案 食品接触符合FDA/EU*要求 主要特性 在三个通过ISO 13485认证的医疗生产线生产 全球统一的配方，提供全球一致性和供应链保 障 变更控制记录的不限于CAS编号级别，降低变 更风险 不含动物源性物质和邻苯二甲酸盐 标准母粒在PE载体中提供，可根据要求在PP 中提供 可以采用针对应用选择的特定树脂提供预着色 配方 药物类型 颜色说明 潘通色号参考 埃万特产品代码 （PE基） 肾上腺素能激动剂组合 浅绿色 373 C PE6M176349 肾上腺素能激动剂 紫色 2583 C PE4M176057 抗感染药 棕褐色 467 C PE8M176130 非甾体类抗炎药 灰色 冷灰色 4 C PE7M176184 甾体类抗炎药 粉色 197 C PE3M176237 免疫调节剂类抗炎药 橄榄绿 5763 C 按要求提供 β-受体阻滞剂 黄色 黄色 C PE1M176160 β-受体阻滞剂组合 深蓝色 281 C PE5M176272 碳酸酐酶抑制剂 橘黄色 1585 C PE2M176089 细胞毒素 黑色 6 C PL9M176008 缩瞳剂 深绿色 348 C PE6M176267 散瞳剂和睫状肌麻痹剂 红色 1797 C PE3M176236 前列腺素类似物 绿松石 326 C PE5M176273 适用医疗保健使用限制—见下文。 在不限制本声明的一般性的情况下，不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用： (1) 接触人体组织或体液长达30天或更长时间； (2)“整形”（整容或重建）手术； (3) 生殖植入物或任何节育器械；或者 (4) 用于支持或维持人类生命的永久性（超过30天）植入式医疗器械中的任何关键组件。

B-T265-1-4 BLUE (PP-10) ECCOH 5943/1(APC60) X ET-8597-1A

XGT-39384-0004-01-1 COOL GRAY 4 X ET-39568-01A1-1 Natural

Novel TPE materials that can overmold onto various engineering plastics also were reported elsewhere (2-4). Figure 3 shows the capillary viscosity of TPE-1 and TPE-2 at 200oC. Krishna Venkataswamy, Jiren Gu and Walter Ripple, “A Novel Robust Polyamide Overmold Thermoplastic Elastomer, John Simons,” RAPRA 2005 4.

Belt & Hose Reinforcement Yarn Colorant Chromatics™ X-Ray Opaque Formulations Belt & Hose Reinforcement Yarn

PolyOne Corporation Page 3 Use of Non-GAAP Measures  This presentation includes the use of both GAAP (generally accepted accounting principles) and non-GAAP financial measures in certain cases throughout this presentation. S&P 500 PolyOne Corporation Page 9 2006 Q1 2015 2015 Target “Where we were” “Where we are” (Est. in 2012) 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 16.2% 12 – 16% Global Specialty Engineered Materials 1.1% 16.3% 12 – 16% Designed Structures & Solutions 1.4% (2012) 2.7% 8 – 10% Performance Products & Solutions 5.5% 6.5% 9 – 12% Distribution 2.6% 5.9% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 69% 65 – 75% 3) ROIC 5.0% 11.4% 15% 4) Adjusted EPS Growth N/A 5% Double Digit Expansion Proof of Performance & 2015 Goals PolyOne Corporation Page 10 Innovation Drives Earnings Growth *Percentage of Specialty Platform revenue from products introduced in last five years $20 $53 2006 2014 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* 14% 27% 2006 2014 Specialty Platform Gross Margin % 20% 44% 2006 2014 Specialty Vitality Index Target ≥ 35% PolyOne Corporation Page 11 Megatrends Aligned with Key End Markets Decreasing Dependence on Fossil Fuels Protecting the Environment Improving Health and Wellness Megatrend End Markets Globalizing and Localizing Health & Wellness Transportation Packaging Consumer PolyOne Corporation Page 12 Prototype Frame Opportunity Scale-up & Test Market Build Business Case Commercial Launch Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 4 11 5 10 6 9 3 4 2 15 9 1 10 4 Breakthrough Platform Derivative A Rich Pipeline of Opportunity Number of Projects 25 14 19 17 18 93 Addressable Market ($ millions) $800 $450 $450 $1,700 PolyOne Corporation Page 13 60% 98% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 Q1 2015 Pension Funding** As of March 31, 2015 Debt Maturities & Pension Funding – 3/31/15 Net Debt / EBITDA* = 2.1x $49 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Debt Maturities As of March 31, 2015 ($ millions) Coupon Rate: 7.500% 7.375% 5.250% ** includes US-qualified pension plans only *TTM 3/31/2015 PolyOne Corporation Page 14 Free Cash Flow and Strong Balance Sheet Fund Investment / Shareholder Return  Expanding our sales, marketing, and technical capabilities  Investing in operational and LSS initiatives  ~75% of capital expenditures fund growth initiatives Organic Growth Acquisitions Share Repurchases Dividends $0.16 $0.20 $0.24 $0.32 $0.40 $0.10 $0.20 $0.30 $0.40 $0.50 2011 2012 2013 2014 2015 Annual Dividend  Targets that expand our: • Specialty offerings • End market presence • Geographic breadth  Synergy opportunities  Adjacent material solutions  Repurchased over 500k shares in Q1 2015  Repurchased 11.8 million shares since early 2013  8.2 million shares are available for repurchase under the current authorization PolyOne Corporation Page 15 PolyOne Core Values Innovation Collaboration Excellence PolyOne Corporation Page 16 The New PolyOne: A Specialty Growth Company Why Invest In PolyOne? 1) Special items are a non-GAAP financial measure.

PANTONE P160-1 C MORADO-PANTONE 0270 -4-1 (V2) SECCIÓN VIOLETA - PANTONE 0240-4-1 (V2)

X ET-16658-01-1 Blk G051349 PEC DARK GREEN 4:100 Shipment Notification - under "Material Header" MSDS - labeled as the "Product Number" (in Section 1)